Description
Clinically Proven to Significantly Reduce Fatigue in ME/CFS Patients
Anhydrous Enol-Oxaloacetate (AEO), 500 mg Capsules, 90-count Bottle
Peer-Reviewed Clinical Trials
-
Springer Nature’s Journal of Translational Medicine:
- Up to 33% reduction in fatigue for ME/CFS patients in 6 weeks
- Up to 47% reduction in fatigue for Long COVID patients that meet ME/CFS criteria in 6 weeks
-
Frontiers In Neurology:
- A significant reduction of fatigue by an average of 25 to 35%
- 40.5% of the oxaloacetate group were classified as "enhanced responders," with an average fatigue reduction of 63%
- Improvements in both mental and physical fatigue
Oxaloacetate CFS™ (AEO) is manufactured in United States cGMP facilities to the highest quality standards. Zero fillers, additives, dyes or flow agents are used.
